VRN07, EGFR exon 20 insertion. Non-Small Cell Lung Cancer
Voronoi’s VRN07 program aims to treat NSCLC by targeting EGFR exon 20 insertion. Voronoi aims to also overcome brain metastasis by developing brain-permeable compound.
보로노이, 美오릭에 폐암 치료제 7200억 기술수출
EGFR/HER2 Exon20 ins. 돌연변이 폐암 및 고형암 치료 뇌 전이암까지도 치료 가능한 정밀 표적신약 美 나스닥 상장사 ORIC에 7200억원 기술이전
Introducing Voronoi Bio
Dr. Son has developed compounds licensed out to global pharmaceuticals, and now introduces Voronoi Bio.
Molecular Modeling: a Foundation for Efficient Drug Development
A breakthrough technology that transformed the existing random and intuitive method, by making the targets and candidates for new drugs visually understandable.
Developing Next-Gen Innovative Drugs
We develop first-in-class and best-in-class global innovative drugs.
VRN02, DYRK1A, Autoimmune diseases
VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.
